

TETRAPHASE PHARMACEUTICALS INC  
 Form 3  
 March 19, 2013

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â FMR LLC		(Month/Day/Year)	TETRAPHASE PHARMACEUTICALS INC [TTPH]	
(Last)	(First)	(Middle)	03/19/2013	
82 DEVONSHIRE STREET			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
BOSTON,Â MAÂ 02109			<input type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner
(City)	(State)	(Zip)	<input type="checkbox"/> Officer	<input checked="" type="checkbox"/> Other
			(give title below)	(specify below)
			Edward C. Johnson 3d	
				6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Series A-1 Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	71,584	\$ (1)	I	by Beacon Bioventures Limited Partnership
Series A-2 Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	93,370	\$ (1)	I	by Beacon Bioventures Limited Partnership
Series B Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	391,212	\$ (1)	I	by Beacon Bioventures Limited Partnership
Series C Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	932,533	\$ (1)	I	by Beacon Bioventures Limited Partnership
Series A-1 Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	485	\$ (1)	I	by Beacon Bioventures Principals Limited Partnership
Series A-2 Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	633	\$ (1)	I	by Beacon Bioventures Principals Limited Partnership
Series B Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	2,651	\$ (1)	I	by Beacon Bioventures Principals Limited Partnership
Series C Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	6,320	\$ (1)	I	by Beacon Bioventures Principals Limited Partnership

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FMR LLC 82 DEVONSHIRE STREET BOSTON, MA 02109	Â	Â X	Â	Edward C. Johnson 3d

## Signatures

Scott C. Goebel, Duly authorized under Powers of Attorney effective as of June 1, 2008, by and on behalf of FMR LLC and its direct and indirect subsidiaries and by and on behalf of Edward C. Johnson 3d

03/19/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All classes of Convertible Preferred Stock will automatically convert into Common Stock upon the consummation of the initial public offering of Common Stock contemplated by the Issuer.

Â

### Remarks:

BeaconÂ BioventuresÂ AdvisorsÂ LimitedÂ PartnershipÂ isÂ theÂ generalÂ partnerÂ ofÂ BeaconÂ BioventuresÂ Limited.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.